Glioblastomas are one of the most malignant and lethal cancers. Despite recent treatment advancements, median survival is only 12 to 16 months. In 2015, the Optune device, a novel, non-invasive ...
NovoCure announced that the first patient has been enrolled in its EF-33 phase 2 pilot trial of Tumor Treating Fields delivered utilizing high-intensity arrays in patients with recurrent glioblastoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback